This reference antibody, mimicking tabalumab, is used in research and development for autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). It targets and neutralizes BAFF (B-cell activating factor, also known as TNFSF13B or CD257), a cytokine essential for B-cell survival and maturation. By blocking BAFF, it reduces excessive B-cell activity and autoantibody production, helping to alleviate inflammation and disease progression. It has been evaluated in preclinical and clinical studies for lowering autoantibody levels, improving symptoms in moderate to severe SLE and RA patients, and modulating the immune response in a targeted manner without widespread immunosuppression. As a reference standard, it is valuable for bioassays, potency testing, and therapeutic development.